Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?

Liver International, Год журнала: 2022, Номер 42(7), С. 1496 - 1502

Опубликована: Янв. 10, 2022

Non-alcoholic fatty liver disease (NAFLD), recently re-defined and re-classified as metabolic dysfunction-associated (MAFLD), has become increasingly prevalent emerged a public health problem worldwide. To date, the precise pathogenic mechanisms underpinning MAFLD are not entirely understood, there is no effective pharmacological therapy for NAFLD/MAFLD. As newly discovered form of iron-dependent programmed cell death, ferroptosis can be involved in development progression various chronic diseases, but connections that link have been fully elucidated. The main characteristics accumulation lipid peroxides reactive oxygen species. In this brief narrative review, its putative role discussed to highlight potential new research directions ideas prevention treatment MAFLD.

Язык: Английский

---

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 28(4), С. 790 - 801

Опубликована: Май 11, 2022

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population and is major public health concern. NAFLD defined by presence hepatic steatosis absence other causes disease. As closely associated with metabolic syndrome, several experts have called for change in nomenclature from to metabolic-associated (MAFLD) better reflect underlying pathophysiology as metabolically driven shift "positive" diagnostic criteria rather than one exclusion. Recent studies suggested that global prevalence MAFLD higher NAFLD, patients more comorbidities compared those NAFLD. Emerging data also suggest all-cause cardiovascular mortality may be In this synopsis, we discuss differences clinical features, outcomes between MAFLD. addition, highlight advantages disadvantages name perspective scientific community, care providers patients.

Язык: Английский

---

SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease

Trends in Endocrinology and Metabolism, Год журнала: 2022, Номер 33(6), С. 424 - 442

Опубликована: Апрель 28, 2022

Язык: Английский

---

Characteristics of gut microbiota in patients with metabolic associated fatty liver disease

Scientific Reports, Год журнала: 2023, Номер 13(1)

Опубликована: Июнь 20, 2023

Abstract Metabolic associated fatty liver disease (MAFLD) is rising in incidence and an increasingly common cause of cirrhosis hepatocellular carcinoma (HCC). Alterations the gut microbiota have been shown to correlate with development progression MAFLD. However, little known regarding differences microbiomes MAFLD patients healthy cohorts, subgroups at abnormal activity hepatic enzymes China. In this study, we enrolled 81 25 volunteers. The fecal was assessed using 16S rRNA gene sequencing metagenomic sequencing. results suggested that Ruminococcus obeum Alistipes were most enriched individuals when compared patients. Microbe‐set Enrichment Analysis (MSEA) showed Dorea , Lactobacillus Megasphaera are group. We also found has negatively related serum glucose (GLU), gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT). Moreover, abundance be significantly overrepresented degree enrichment increased increasing enzyme. An increase combined decreases appears characteristic Further study may provide a novel insight into pathogenesis as well treatment strategy.

Язык: Английский

---

MAFLD as part of systemic metabolic dysregulation

Hepatology International, Год журнала: 2024, Номер 18(S2), С. 834 - 847

Опубликована: Апрель 9, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and atherosclerosis

Current Diabetes Reports, Год журнала: 2024, Номер 24(7), С. 158 - 166

Опубликована: Май 3, 2024

Язык: Английский

---

Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study

Frontiers in Endocrinology, Год журнала: 2024, Номер 15

Опубликована: Сен. 19, 2024

Objective To explore the link between plasma aldosterone concentration (PAC) and prevalence of metabolic dysfunction-related fatty liver disease (MAFLD) in hypertensive patients. Methods We analyzed data from 41,131 hospitalized patients January 1, 2014, to December 31, 2023. Multivariate logistic regression models tested associations, with threshold, subgroup, sensitivity analyses conducted validate findings. Results For each 5-unit increase PAC, risk MAFLD rose by 1.57 times, consistent even fully adjusted model. The odds ratios for Q2, Q3, Q4 groups compared Q1 were 1.21, 2.12, 3.14, respectively. A threshold effect was observed at 14 ng/dL, subgroup supporting these results. Conclusions This study reveals a significant positive association elevated PAC levels These findings underscore imperative further large-scale, prospective studies expand upon this correlation.

Язык: Английский

---

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis

Annals of Hepatology, Год журнала: 2022, Номер 28(1), С. 100762 - 100762

Опубликована: Сен. 29, 2022

Type 2 Diabetes Mellitus (T2DM) is comorbidity commonly presenting with fatty liver. A recently proposed definition of "metabolic associated liver disease" (MAFLD) thought to replace non-alcoholic disease (NAFLD). Yet, despite the significant prevalence T2DM among liver, there remains limited evidence on impact change in T2DM.The current study uses data from United States National Health and Nutrition Examination Survey (NHANES) 1999 2018. Survival analysis was conducted a cox regression sub-distribution hazard ratio for competing risk events.6727 patients had diagnosis T2DM. 4982 individuals MAFLD 2032 were MAFLD(+)/NAFLD(-), while 2950 MAFLD(+)/NAFLD(+). The new increased by 68.89%. Patients who classified as MAFLD(+)/NAFLD(-) at higher major adverse cardiovascular events, advanced fibrosis, all-cause cardiovascular-related mortality compared In viral hepatitis significantly increases odds fibrosis (OR: 6.77, CI: 3.92 11.7, p < 0.001) (HR: 1.75, 1.29 2.40, 0.001).The identification treatment NAFLD concern premature results an over-diagnosis exaggerated mortality, morbidity causes further heterogeneity disease/NAFLD.

Язык: Английский

---

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease

Journal of Gastroenterology and Hepatology, Год журнала: 2022, Номер 37(5), С. 795 - 811

Опубликована: Янв. 26, 2022

The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD). panel consisted experts in field gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine, public health. A modified Delphi process was used to prepare statements. recognized high increasing prevalence consequent anticipated increase liver-related complications mortality. Cardiovascular is leading cause mortality MAFLD patients; therefore, cardiovascular risk assessment management important. simple clear referral pathway agreed upon, so that patients with more severe can be linked gastroenterology/hepatology care, while less remain primary care or where they are best managed. Lifestyle intervention cornerstone MAFLD. provided use statin, angiotensin-converting enzyme inhibitor angiotensin receptor blocker, sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 agonist, pioglitazone, vitamin E, metformin, as well recommendations screening gastroesophageal varices hepatocellular carcinoma, transplantation patients. Increasing awareness knowledge various stakeholders incorporating into existing noncommunicable disease-related programs activities important steps tackle disease. These statements will serve guide clinicians other stakeholders.

Язык: Английский

---

From HFpEF to “metabolic (dysfunction)-associated HFpEF”: Time to act

Science Bulletin, Год журнала: 2024, Номер 69(7), С. 850 - 852

Опубликована: Янв. 8, 2024

Язык: Английский

---